Targeted therapy pill with chemo before surgery for ALK-positive lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study tests whether giving a new targeted pill (iruplaltinib) along with chemotherapy before surgery can help shrink tumors and improve outcomes for people with ALK-positive lung cancer. Participation involves taking study drugs, having tests, and then undergoing surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with non-squamous non-small cell lung cancer that is ALK-positive (a specific gene change).
- Your cancer is stage IIA to IIIB, meaning it is locally advanced but can be removed with surgery.
- You have not had prior cancer treatment for this lung cancer, such as chemotherapy or radiation.
- You have not had other cancer in the last 5 years, except for certain easily treated types.
- Your heart, liver, kidneys, and blood counts are healthy enough for surgery and study drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a targeted therapy pill (called iruplinalkib) given before surgery for people with a certain type of lung cancer (ALK-positive NSCLC). The goal is to see if the pill can shrink the tumor, making it easier to remove completely during surgery.
This study tests whether taking a pill called iruplinalkib after surgery for early-stage ALK-positive lung cancer can help keep cancer from coming back. Iruplinalkib is a type of targeted therapy that blocks cancer cells with a specific ALK gene change.
This study looks at whether giving a targeted therapy pill (lorlatinib) before surgery can help shrink ALK-positive lung cancer and improve outcomes. It also aims to understand why some tumors may not respond to this treatment.
This study tests a combination of two targeted medicines for people with a specific type of non-small cell lung cancer (NSCLC) that has the ALK gene change. The goal is to see if giving these drugs before surgery can shrink tumors and improve outcomes.
This trial tests whether taking the targeted therapy Ensartinib (which blocks ALK) along with standard chemotherapy before surgery can help shrink ALK-positive lung cancer and improve outcomes. It is for people who have not yet had treatment and whose cancer is at a stage that can be removed with surgery.
This Phase 2 study tests whether ALK-targeted drugs can shrink or control advanced squamous cell cancer that has spread. You may be eligible if your tumor has an ALK gene rearrangement and you have not had prior cancer medicines for this stage.
Hear when a new ALK-positive Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.